Aflibercept: A Review of Its Use in Diabetic Macular Oedema

被引：9
作者：
Keating, Gillian M. [1 ]
机构：
[1] Springer, Auckland, New Zealand
来源：
DRUGS | 2015年 / 75卷 / 10期
关键词：
ENDOTHELIAL GROWTH-FACTOR; VEGF TRAP-EYE; INTRAVITREAL AFLIBERCEPT; DA VINCI; RANIBIZUMAB; INJECTION; OUTCOMES; BEVACIZUMAB; RETINOPATHY; PHASE-2;
D O I：
10.1007/s40265-015-0421-y
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aflibercept (Eylea (R)) is an anti-vascular endothelial growth factor agent indicated for intravitreal use in the treatment of diabetic macular oedema. In patients with diabetic macular oedema, significantly greater improvements from baseline to week 52 in visual acuity were seen with intravitreal aflibercept versus macular laser photocoagulation in the phase III VISTA-DME and VIVID-DME trials, and versus intravitreal bevacizumab or ranibizumab in those with worse visual acuity at baseline (i.e. Early Treatment Diabetic Retinopathy Study letter score of <69) in the phase III PROTOCOL-T trial. Intravitreal aflibercept was generally well tolerated in patients with diabetic macular oedema. In conclusion, intravitreal aflibercept is an important new treatment for diabetic macular oedema.
引用
收藏
页码：1153 / 1160
页数：8
相关论文
共 46 条
[1]   Angiogenic pathways in diabetic retinopathy [J].
Aiello, LP .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (08) :839-841
[2]   THE EFFECTS OF AFLIBERCEPT ON THE VIABILITY AND METABOLISM OF OCULAR CELLS IN VITRO [J].
Ammar, David A. ;
Mandava, Naresh ;
Kahook, Malik Y. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2013, 33 (05) :1056-1061
[3]   Introduction [J].
不详 .
DIABETES CARE, 2015, 38 :S1-S2
[4]   Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions [J].
Carmeliet, P ;
Moons, L ;
Luttun, A ;
Vincenti, V ;
Compernolle, V ;
De Mol, M ;
Wu, Y ;
Bon, F ;
Devy, L ;
Beck, H ;
Scholz, D ;
Acker, T ;
DiPalma, T ;
Dewerchin, M ;
Noel, A ;
Stalmans, I ;
Barra, A ;
Blacher, S ;
Vandendriessche, T ;
Ponten, A ;
Eriksson, U ;
Plate, KH ;
Foidart, JM ;
Schaper, W ;
Charnock-Jones, DS ;
Hicklin, DJ ;
Herbert, JM ;
Collen, D ;
Persico, MG .
NATURE MEDICINE, 2001, 7 (05) :575-583
[5]   Pharmacokinetic Properties of Intravitreal I-124-Aflibercept in a Rabbit Model Using PET/CT [J].
Christoforidis, John B. ;
Williams, Michelle M. ;
Kothandaraman, Shankaran ;
Kumar, Krishan ;
Epitropoulos, Frank J. ;
Knopp, Michael V. .
CURRENT EYE RESEARCH, 2012, 37 (12) :1171-1174
[6]   Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells [J].
Deissler, Heidrun L. ;
Lang, Gerhard K. ;
Lang, Gabriele E. .
EXPERIMENTAL EYE RESEARCH, 2014, 122 :20-31
[7]   An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema [J].
Do, D. V. ;
Nguyen, Q. D. ;
Shah, S. M. ;
Browning, D. J. ;
Haller, J. A. ;
Chu, K. ;
Yang, K. ;
Cedarbaum, J. M. ;
Vitti, R. L. ;
Ingerman, A. ;
Campochiaro, P. A. .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2009, 93 (02) :144-149
[8]   One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema [J].
Do, Diana V. ;
Quan Dong Nguyen ;
Boyer, David ;
Schmidt-Erfurth, Ursula ;
Brown, David M. ;
Vitti, Robert ;
Berliner, Alyson J. ;
Gao, Bo ;
Zeitz, Oliver ;
Ruckert, Rene ;
Schmelter, Thomas ;
Sandbrink, Rupert ;
Heier, Jeff S. .
OPHTHALMOLOGY, 2012, 119 (08) :1658-1665
[9]   The DA VINCI Study: Phase 2 Primary Results of VEGF Trap-Eye in Patients with Diabetic Macular Edema [J].
Do, Diana V. ;
Schmidt-Erfurth, Ursula ;
Gonzalez, Victor H. ;
Gordon, Carmelina M. ;
Tolentino, Michael ;
Berliner, Alyson J. ;
Vitti, Robert ;
Rueckert, Rene ;
Sandbrink, Rupert ;
Stein, David ;
Yang, Ke ;
Beckmann, Karola ;
Heier, Jeff S. .
OPHTHALMOLOGY, 2011, 118 (09) :1819-1826
[10]  
European Medicines Agency, 2014, LUC RAN EU SUMM PROD
12345